Masaaki Okutsu

Masaaki Okutsu

Auto-generated profile, based on publicly available information

Masaaki Okutsu

Department of Cardiovascular Medicine, New Tokyo Hospital, Chiba, Japan; Department of Cardiology, Tokai University Hachioji Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HWHiroki Watanabe
Hiroki Watanabe
NONeiko Ozasa
Neiko Ozasa
TMTakeshi Morimoto
Takeshi Morimoto
HSHiroki Shiomi
Hiroki Shiomi
BBBao Bingyuan
Bao Bingyuan
OIon behalf of the CAPITAL-RCT investigators
on behalf of the CAPITAL-RCT investigators
Despite its recommendation by the current guidelines, the role of long-term oral beta-blocker therapy has never been evaluated by randomized trials in uncomplicated ST-segment elevation myocardial infarction (STEMI) patients without heart failure, left ventricular dysfunction or ventricular arrhythmia who underwent primary percutaneous coronary intervention (PCI). In a multi-center, open-label, randomized controlled trial, STEMI patients with successful primary PCI within 24 hours from the onset and with left ventricular ejection fraction (LVEF) ≥40% were randomly assigned in a 1-to-1 fashion either to the carvedilol group or to the no beta-blocker group within 7 days after primary PCI. The primary endpoint is a composite of all-cause death, myocardial infarction, hospitalization for heart failure, and hospitalization for acute coronary syndrome. Between August 2010 and May 2014, 801 patients were randomly assigned to the carvedilol group (N = 399) or the no beta-blocker group (N = 402) at 67 centers in Japan. The carvedilol dose was up-titrated from 3.4±2.1 mg at baseline to 6.3±4.3 mg at 1-year. During median follow-up of 3.9 years with 96.4% follow-up, the cumulative 3-year incidences of both the primary endpoint and any coronary revascularization were not significantly different between the carvedilol and no beta-blocker groups (6.8% and 7.9%, P = 0.20, and 20.3% and 17.7%, P = 0.65, respectively). There also was no significant difference in LVEF at 1-year between the 2 groups (60.9±8.4% and 59.6±8.8%, P = 0.06) Long-term carvedilol therapy added on the contemporary evidence-based medications did not seem beneficial in selected STEMI patients treated with primary PCI. CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-scale Randomized Controlled Trial) ClinicalTrials.gov.number, NCT 01155635.

1 January 2018 in Circulation Journal
Verified
Journal Article
Open access
PDF file
TMTetsuo Minamino
Tetsuo Minamino
SHShuichiro Higo
Shuichiro Higo
RARyo Araki
Ryo Araki
SHShungo Hikoso
Shungo Hikoso
DNDaisaku Nakatani
Daisaku Nakatani
EIEPO-AMI-II Investigators
EPO-AMI-II Investigators
Background:Erythropoietin (EPO) has antiapoptotic and tissue-protective effects, but previous clinical studies using high-dose EPO have not shown cardioprotective effects, probably because of platelet activation and a lack of knowledge regarding the optimal dose. In contrast, a small pilot study using low-dose EPO has shown improvement in left ventricular function without adverse cardiovascular events. Methods and Results:We performed a multicenter (25 hospitals), prospective, randomized, double-blind, placebo-controlled, dose-finding study to clarify the efficacy and safety of low-dose EPO in patients with ST-segment elevation myocardial infarction (STEMI) under the Evaluation System of Investigational Medical Care of the Ministry of Health, Labor and Welfare of Japan. In total, 198 STEMI patients with low left ventricular ejection fraction (LVEF <50%) were randomly assigned to receive intravenous administration of EPO (6,000 or 12,000 IU) or placebo within 6 h of successful percutaneous coronary intervention. At 6 months, there was no significant dose-response relationship in LVEF improvement among the 3 groups tested (EPO 12,000 IU: 5.4±9.3%, EPO 6,000 IU: 7.3±7.7%, Placebo: 8.1±8.3%, P=0.862). Low-dose EPO also did not improve cardiac function, as evaluated by 99 mTc-MIBI SPECT or NT-proBNP at 6 months and did not increase adverse events. Conclusions:Administration of low-dose EPO did not improve LVEF at 6 months in STEMI patients (UMIN000005721).

4 January 2022 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
MOMasaaki Okutsu
Masaaki Okutsu
SMSatoru Mitomo
Satoru Mitomo
TOToru Ouchi
Toru Ouchi
HYHisahito Yuki
Hisahito Yuki
TUTakahiro Ueno
Takahiro Ueno
SNSunao Nakamura
Sunao Nakamura

9 July 2023 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
MOMasaaki Okutsu
Masaaki Okutsu
SMSatoru Mitomo
Satoru Mitomo
HOHirokazu Onishi
Hirokazu Onishi
ANAkihiro Nakajima
Akihiro Nakajima
HYHiroto Yabushita
Hiroto Yabushita
SNSunao Nakamura
Sunao Nakamura

11 April 2018 in Heart and Vessels
Verified
Journal Article
Open access
PDF file
MOMasaaki Okutsu
Masaaki Okutsu
THTakeshi Horio
Takeshi Horio
HTHisataka Tanaka
Hisataka Tanaka
MAMaki Akiyama
Maki Akiyama
NONiro Okimoto
Niro Okimoto
YIYuji Ikari
Yuji Ikari
Attenuated plaque on intravascular ultrasound (IVUS) and low attenuation plaque on computed tomography angiography (CTA) are associated with no-reflow phenomenon during percutaneous coronary intervention (PCI). However, evaluation by a single modality has been unable to satisfactorily predict this phenomenon. We investigated whether the combination of IVUS and CTA findings can ameliorate the predictive potential for no-reflow phenomenon after stent implantation during PCI in stable coronary artery disease (CAD). A total of 988 lesions of 707 stable CAD patients who underwent coronary CTA before PCI were enrolled. PCI was performed with preprocedural IVUS and stent implantation. As for plaque characters, very low attenuation plaque (CTA v-LAP) whose minimum density was < 0 Hounsfield units on CTA and attenuated plaque (IVUS AP) on IVUS were evaluated. No-reflow phenomenon was observed in 22 lesions (2.2%) of 19 patients (2.7%). Both CTA v-LAP and IVUS AP were much more frequently observed in patients with no-reflow phenomenon. Positive (PPV) and negative predictive values (NPV) and accuracy for prediction of no-reflow were almost equivalent between CTA v-LAP (13.2, 99.6, and 87.0%) and IVUS AP (15.7, 99.8, and 89.0%). The combination of CTA v-LAP and IVUS AP markedly ameliorated PPV (31.7%) without deterioration of NPV (99.7%) and increased the diagnostic accuracy (95.5%). These findings showed that the combination of CTA v-LAP and IVUS AP improved the predictive power for no-reflow phenomenon after coronary stenting in stable CAD patients, suggesting the usefulness of combined estimation by using CTA and IVUS for predicting no-reflow phenomenon during PCI in clinical practice.

8 February 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
YWYusuke Watanabe
Yusuke Watanabe
SMSatoru Mitomo
Satoru Mitomo
TNToru Naganuma
Toru Naganuma
SMSatoshi Matsuoka
Satoshi Matsuoka
ACAlaide Chieffo
Alaide Chieffo
ACAntonio Colombo
Antonio Colombo